• In June 2026, AbCellera Biologics announced a preclinical research collaboration, option, and license agreement with Jazz Pharmaceuticals to discover and develop next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors, with Jazz gaining exclusive global development and commercialization rights on exercising program-specific options.
• The deal structure, featuring US$56,000,000 in upfront payments for two programs, a further US$28,000,000 on a third program’s initiation, and the potential for very large per-program milestones plus royalties, highlights how Jazz is using external innovation to expand its immuno-oncology pipeline.
• Next, we’ll examine how this immuno-oncology collaboration, and its potential to broaden Jazz’s oncology pipeline, may influence its investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

Jazz Pharmaceuticals Investment Narrative Recap

To own Jazz, you need to be comfortable with a company that is trying to offset looming oxybate patent and pricing pressures by building a broader oncology and neuroscience portfolio. The AbCellera collaboration adds very early stage GI cancer T‑cell engagers, but it does not change the fact that near term attention is still on Zepzelca and Ziihera execution and on how sharply oxybate revenues might fall as generics arrive.

The AbCellera deal sits alongside Jazz’s existing oncology efforts, including its work to expand Ziihera (zanidatamab) into first line HER2 positive gastroesophageal adenocarcinoma, where a priority review filing is already in progress. Seeing Jazz simultaneously push late stage assets like Ziihera while seeding earlier programs with AbCellera helps frame how the company is trying to balance nearer term oncology catalysts with longer dated pipeline bets.

Yet, while these efforts aim to broaden Jazz’s oncology base, investors still need to think carefully about what happens if oxybate generics bite faster and harder than expected...

Jazz Pharmaceuticals' narrative projects $5.4 billion revenue and $1.4 billion earnings by 2029. This requires 6.9% yearly revenue growth and about a $1.4 billion earnings increase from $29.5 million today.

Uncover how Jazz Pharmaceuticals' forecasts yield a $257.00 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Compared with the baseline view, the lowest ranked analysts sound far more cautious, assuming only about 3.5% annual revenue growth to roughly US$4.9 billion and earnings of about US$1.0 billion by 2029, and they focus heavily on the risk that oncology sales could stagnate even with new collaborations like AbCellera’s, so it is worth weighing how this new GI cancer program might eventually shift those more pessimistic assumptions.

Explore 3 other fair value estimates on Jazz Pharmaceuticals - why the stock might be worth 16% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Jazz Pharmaceuticals research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Jazz Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Jazz Pharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.